Abecma (idecabtagene vicleucel) CAR‑T therapy coverage
Customize your policy alerts
Sign up for Aspirus Arise POLICY 250 alerts
Get alerted when POLICY 250 changes without checking for updates manually.
Monitor payer policy activity
Defines prior authorization, coverage criteria, dosing, and exclusions for Abecma (idecabtagene vicleucel) for Aspirus Medicare Plans for treatment of relapsed/refractory multiple myeloma.
Added patient has received at least three prior lines of therapy as a new option for approval.
Revised Abecma dose from 'up to 460 x 10^6 CAR-positive T-cells' to 'up to 510 x 10^6 CAR-positive T-cells'.
Revised required prior lines threshold from four or more to two or more lines of systemic therapy (with specified agents) as primary pathway to approval.
Approval duration set to 6 months to allow preparation and administration of a single dose.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.